title: Osteoporosis: pathogenesis, new therapies and surgical implications.
abstract: Many developments occurred in the realm of bone healing in recent years. Genetic discoveries, new proteins affecting bone health, and new treatments have steered our treatment of traumatic and iatrogenic fractures in new directions. Osteoporosis strikes many subsets of the world population, including: women, the elderly, and those suffering from arthritis, autoimmune diseases, HIV, and the immunocompromised. This disease predisposes people to an increased risk of low trauma and fragility fractures. The baby boomer generation and an increasing lifespan may burden the economy by creating such a large group susceptible to such a potentially devastating disease. The novel treatments and coping with the potentially challenging surgical implications will aide the podiatric physician in both medical and surgical management of osteoporosis.
authors: West Los Angeles-Veterans Administration Medical Center, Los Angeles, and Samuel Meritt College of Podiatric Medicine, Oakland, CA 94609, USA. dr_labovitz@feetandankles.com
authors: Jonathan M
authors: JM
authors: Labovitz
authors: Kate
authors: K
authors: Revill
mesh_terms: D001168:Arthritis / Q000150:complications; D001327:Autoimmune Diseases / Q000150:complications; D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D013514:Surgical Procedures, Operative
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020849:Raloxifene Hydrochloride; D002116:Calcitonin